Abstract
The treatment of allergic bronchopulmonary aspergillosis (ABPA) focuses on controlling the inflammatory host response to Aspergillus antigens. For this reason, systemic steroids are the cornerstone of therapy. As acute ABPA is a form of asthma, standard asthma care should be also be used. An attempt should be made to taper patients off steroids after acute exacerbations. However, this is often problematic and cannot be achieved. Azoles show promise in this instance as steroid-sparing agents. Cystic fibrosis patients are at high risk of developing ABPA. Such patients present management dilemmas as it is often challenging to distinguish cystic fibrosis from ABPA exacerbations.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
